HONG KONG—WuXi Biologics (HKG: 2269), a leading global open biopharmaceutical technology platform company, has announced its intention to acquire the remaining 30% stake in WuXi HaiDe, a non-wholly owned subsidiary specializing in comprehensive end-to-end vaccine contract research, development, and manufacturing organization services. The total consideration for this acquisition is USD 108.5 million, equivalent to approximately HKD 846.3 million.
Following the completion of this transaction, WuXi HaiDe will become a wholly-owned subsidiary of WuXi Biologics, with its financial results continuing to be consolidated into the financial statements of WuXi Biologics. This move is expected to strengthen WuXi Biologics’ position in the vaccine sector by leveraging WuXi HaiDe’s expertise in vaccine development and manufacturing services.
WuXi HaiDe has been a key player in the vaccine contract development and manufacturing organization (CDMO) industry, offering a comprehensive suite of services from preclinical to commercial stages. The acquisition underscores WuXi Biologics’ commitment to expanding its capabilities and enhancing its service offerings to meet the growing demand for vaccines and biologics globally. -Fineline Info & Tech
